Evaluating the Necessity of Long-Term Beta-Blocker Therapy Post-Myocardial Infarction
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on November 18th, 2024
|
Beta-blockers are the standard treatment for individuals who have experienced a myocardial infarction; however, this guidance was established before the introduction of myocardial reperfusion techniques and modern pharmacotherapy. Recent large-scale observational studies have not found a clear benefit of long-term beta-blocker use after myocardial infarction. Supported by funding from the French Ministry of Health, a study was initiated to determine the optimal duration for beta-blocker therapy following myocardial infarction.
The randomized controlled trial involved 3,698 patients who had experienced a myocardial infarction, with two-thirds of the cohort having suffered an ST-segment elevation myocardial infarction and approximately 3% having a history of stroke or transient ischemic attack. The median left ventricular ejection fraction was around 60%, and about 25% of patients still reported residual angina. At the trial's start, all patients were receiving beta-blockers, but half were randomly assigned to discontinue this treatment. After a three-year follow-up, the researchers found that there was no significant difference in the risk of death, recurrent myocardial infarction, or stroke between patients who stopped or continued using beta blockers. A slight, but not statistically significant, reduction in hospitalization for cardiovascular reasons was observed in those who continued beta-blockers. An evaluation of side effects in the continuation group indicated that beta-blocker therapy did not impact quality of life.
The randomized controlled trial involved 3,698 patients who had experienced a myocardial infarction, with two-thirds of the cohort having suffered an ST-segment elevation myocardial infarction and approximately 3% having a history of stroke or transient ischemic attack. The median left ventricular ejection fraction was around 60%, and about 25% of patients still reported residual angina. At the trial's start, all patients were receiving beta-blockers, but half were randomly assigned to discontinue this treatment. After a three-year follow-up, the researchers found that there was no significant difference in the risk of death, recurrent myocardial infarction, or stroke between patients who stopped or continued using beta blockers. A slight, but not statistically significant, reduction in hospitalization for cardiovascular reasons was observed in those who continued beta-blockers. An evaluation of side effects in the continuation group indicated that beta-blocker therapy did not impact quality of life.